ArticleGenes2026

MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening.

Hirofumi Yoshino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.